Zacks Investment Research upgraded shares of uniQure NV (NASDAQ:QURE) from a sell rating to a hold rating in a report released on Wednesday.

According to Zacks, “UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company’s product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. “

QURE has been the topic of a number of other research reports. Piper Jaffray Cos. reaffirmed a buy rating on shares of uniQure NV in a research report on Thursday, June 30th. Cowen and Company reaffirmed a buy rating on shares of uniQure NV in a research report on Thursday, July 28th. Leerink Swann reaffirmed an outperform rating and set a $27.00 target price on shares of uniQure NV in a research report on Monday, August 29th. WallachBeth Capital dropped their target price on shares of uniQure NV from $60.00 to $35.00 and set a buy rating on the stock in a research report on Wednesday, June 15th. Finally, HC Wainwright began coverage on shares of uniQure NV in a research report on Thursday, August 4th. They set a buy rating and a $21.00 target price on the stock. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $28.10.

Shares of uniQure NV (NASDAQ:QURE) traded down 1.226% during mid-day trading on Wednesday, reaching $7.655. 14,343 shares of the company traded hands. The stock’s market capitalization is $192.36 million. The stock’s 50 day moving average is $8.23 and its 200 day moving average is $10.36. uniQure NV has a 52-week low of $6.68 and a 52-week high of $27.65.

uniQure NV (NASDAQ:QURE) last announced its earnings results on Thursday, August 25th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.89) by $0.02. uniQure NV had a negative net margin of 537.62% and a negative return on equity of 61.96%. On average, analysts anticipate that uniQure NV will post ($3.71) earnings per share for the current year.

Several large investors have recently modified their holdings of QURE. Point72 Asset Management L.P. increased its stake in shares of uniQure NV by 105.7% in the second quarter. Point72 Asset Management L.P. now owns 562,447 shares of the company’s stock valued at $4,145,000 after buying an additional 288,982 shares in the last quarter. Highbridge Capital Management LLC bought a new position in shares of uniQure NV during the second quarter valued at about $175,000. Spark Investment Management LLC increased its position in shares of uniQure NV by 28.5% in the second quarter. Spark Investment Management LLC now owns 380,400 shares of the company’s stock valued at $2,803,000 after buying an additional 84,400 shares during the period. ProShare Advisors LLC increased its position in shares of uniQure NV by 9.9% in the second quarter. ProShare Advisors LLC now owns 18,479 shares of the company’s stock valued at $136,000 after buying an additional 1,666 shares during the period. Finally, TFS Capital LLC increased its position in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares during the period. Institutional investors own 32.38% of the company’s stock.

About uniQure NV

uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.

5 Day Chart for NASDAQ:QURE

Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with Analyst Ratings Network's FREE daily email newsletter.